Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 7678 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 10081 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 11487 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 12664 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 12725 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 13638 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 15053 | Peak area normalized | male | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 15181 | Peak area normalized | male | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 15225 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 15938 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16094 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16135 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16296 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16502 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 16705 | Peak area normalized | male | Normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 17291 | Peak area normalized | male | Normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 17551 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 17583 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 17938 | Peak area normalized | female | Diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 19472 | Peak area normalized | female | Pre-diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 19568 | Peak area normalized | male | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 21509 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 21893 | Peak area normalized | female | Pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 22175 | Peak area normalized | male | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 24024 | Peak area normalized | female | Diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | AZELAIC ACID (M-H)- | 24220 | Peak area normalized | male | Diabetic | no neuropathy |